|
||||||||||||||||||||||
|
|
Alternate Title Phase III Study of Fentanyl Sublingual Spray for Breakthrough Cancer Pain in Patients Who are Opioid Tolerant
Trial Description Fentanyl sublingual spray may help relieve breakthrough pain in patients receiving opioids for cancer pain. This phase III trial is studying how well fentanyl sublingual spray works in treating patients with breakthrough cancer pain. Eligibility criteria include the following:
Final eligibility for a clinical trial is determined by the health professionals conducting the trial. Patients will receive fentanyl sublingual spray for up to 17 weeks. They will also fill out questionnaires. Important: For more details about this trial, refer to the Health Professional version of the trial summary. If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site. Trial Lead Organizations InSys Therapeutics, Incorporated
Related Information PDQ® clinical trial INSYS-INS-05-001
|
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |